Vector Development

Rabies Virus Developed as Potential Vaccine for HIV-1

Published in Gene Therapy Weekly, February 24th, 2000

A recombinant rabies virus (RV) has potential as a live-viral vaccine for HIV-1, reported researchers from the United States.

"Recombinant, replication competent RV vaccine strain-based vectors expressing HIV-1 envelope protein (gp160) were constructed from both a laboratory adapted (CXCR4-tropic) and a primary (dual-tropic) HIV-1 isolate," said M.J. Schnell and colleagues from the Dorance H. Hamilton Laboratories, USA.

Schnell et al. presented data from their work at the 7th Conference on Retroviruses and Opportunistic Infections, held January 30 - February 2, 2000, in San Francisco, California, USA. The title of their presentation was "Recombinant...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2000-02-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry